A 52-year-old man with a 10-year history of cirrhosis due to hepatitis B presents with right upper quadrant pain and weight loss over 3 months. Ultrasound shows a 3.5 cm nodule in the right lobe of the liver. Serum alpha-fetoprotein (AFP) is 890 ng/mL (normal <20 ng/mL). What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has established cirrhosis with a nodule and markedly elevated AFP — a classic presentation suspicious for hepatocellular carcinoma (HCC). ## Diagnostic Algorithm for HCC **Key Point:** In a cirrhotic patient with a nodule 1–2 cm, AFP >400 ng/mL, or a nodule >1 cm with AFP 20–400 ng/mL, imaging (CT or MRI with contrast) is the diagnostic standard and does NOT require biopsy confirmation. **High-Yield:** The AASLD (American Association for the Study of Liver Diseases) and EASL (European Association for the Study of the Liver) guidelines state that a nodule >1 cm in a cirrhotic liver with typical imaging features (arterial phase enhancement + venous/delayed phase washout) on ONE imaging modality (CT or MRI) is diagnostic of HCC without biopsy. ## Why Contrast-Enhanced Imaging is Next 1. **Staging requirement**: CT or MRI defines the extent of disease (size, number, vascular invasion, extrahepatic spread), which determines treatment eligibility (resection, transplant, transarterial chemoembolization [TACE], sorafenib). 2. **Non-invasive diagnosis**: The combination of cirrhosis + nodule >1 cm + elevated AFP + typical imaging pattern = HCC diagnosis; biopsy adds no diagnostic value and risks seeding. 3. **Treatment planning**: Imaging findings guide whether the patient is a candidate for curative (resection/transplant) vs. palliative (TACE/sorafenib) therapy. ## Why Other Options Are Incorrect **Observation with repeat AFP:** Delays diagnosis and staging in a patient with imaging and biochemical evidence of HCC. AFP trends are useful for surveillance in at-risk patients without a nodule, not for a patient with a nodule and markedly elevated AFP. **Biopsy:** Unnecessary when imaging criteria are met; carries risk of hemorrhage (especially in cirrhosis), seeding, and does not change management in this scenario. **Immediate sorafenib:** Premature without staging. Sorafenib is indicated for advanced HCC (BCLC stage C) or when other therapies are not feasible. Staging imaging may reveal the patient is a candidate for resection or transplant (potentially curative). ```mermaid flowchart TD A[Cirrhotic patient + nodule 1-2 cm + elevated AFP]:::outcome --> B{Nodule size?}:::decision B -->|>1 cm| C[Contrast-enhanced CT or MRI]:::action C --> D{Typical HCC imaging pattern?}:::decision D -->|Yes| E[HCC diagnosed]:::outcome E --> F{Staging & treatment planning}:::action F --> G[Assess for resection/transplant/TACE/sorafenib]:::action B -->|<1 cm| H[Ultrasound surveillance every 3-4 months]:::action ```